EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY-NC-ND 4.0

Next‐generation sequencing clarified why first‐line treatment with osimertinib was ineffective in an autopsied case of EGFR ‐mutated lung squamous cell carcinoma

Tadashi Nishimura iD, Takumi Fujiwara, Hajime Fujimoto, Hirotoshi Tarumi, Chikashi Tsuji, Soichi Iwanaka, Yasumasa Sakakura, Masahiro Naito, Yoshinaga Okugawa, Taro Yasuma, Esteban Cesar Gabazza iD, Yasuhiro Oomoto und 2 weitere

Thoracic Cancer · 2023

DOI: 10.1111/1759-7714.14807 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Thoracic Cancer, 2023. Verfasst von Tadashi Nishimura und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonary Medicine, Mie Chuo Medical Center, Tsu, Japan. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Carcinoma, Squamous Cell. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Epidermal growth factor receptor (EGFR)‐mutated squamous cell carcinoma (SCC) is less common than adenocarcinoma. The third‐generation EGFR‐tyrosine kinase inhibitor, osimertinib, is effective in EGFR‐mutated lung adenocarcinoma, but its efficacy in EGFR‐mutated lung SCC is unclear. The patient was an 83‐year‐old male. He was diagnosed with SCC of the lung, and molecular analysis revealed that the tumor was positive for EGFR exon19 deletion. He was treated with osimertinib 80 mg/day. No adverse events were observed, but after 18 days of therapy, he complained of dyspnea, and a computed tomography scan showed enlarged lung cancer. The case was categorized as a progressive disease. The patient died 3 weeks later. The autopsy findings confirmed the diagnosis of lung SCC, with morphology and immunohistochemical staining identical to the tumor obtained by bronchoscopy. Next‐generation sequencing showed the presence of TP53 R158L , CDK6 , and KRAS amplifications. The current case report shows that next‐generation sequencing can explain why osimertinib is ineffective in EGFR‐mutated SCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsCarcinoma, Squamous CellMaleHumansAged, 80 and overAutopsyMutationErbB ReceptorsLungHigh-Throughput Nucleotide SequencingProtein Kinase InhibitorsAcrylamidesAniline CompoundsIndolesPyrimidines

Stichwörter der Autor:innen

EGFR mutationautopsynext-generation sequencingnon-squamous cell lung cancerosimertinib

Substanzen

ErbB ReceptorsProtein Kinase InhibitorsosimertinibAcrylamidesAniline CompoundsIndolesPyrimidinesEGFR protein, human

Autor:innen und Institutionen

  • Department of Pulmonary Medicine, Mie Chuo Medical Center, Tsu, Japan.
  • Department of Pulmonary and Critical Care Medicine, Mie University Faculty and Graduate School of Medicine, Tsu, Japan.
  • Department of Genomic Medicine, Mie University Hospital, Tsu, Japan.
  • Department of Immunology, Mie University Faculty and Graduate School of Medicine, Tsu, Japan.

ORCID-Profile: Tadashi Nishimura, Esteban Cesar Gabazza

Zitieren

APA

Nishimura, T., Fujiwara, T., Fujimoto, H., Tarumi, H., Tsuji, C., Iwanaka, S., Sakakura, Y., Naito, M., Okugawa, Y., Yasuma, T., Gabazza, E. C., Oomoto, Y., Kobayashi, T., & Ibata, H. (2023). Next‐generation sequencing clarified why first‐line treatment with osimertinib was ineffective in an autopsied case of EGFR ‐mutated lung squamous cell carcinoma. Thoracic Cancer. https://doi.org/10.1111/1759-7714.14807

Vancouver

Nishimura T, Fujiwara T, Fujimoto H, Tarumi H, Tsuji C, Iwanaka S, et al. Next‐generation sequencing clarified why first‐line treatment with osimertinib was ineffective in an autopsied case of EGFR ‐mutated lung squamous cell carcinoma. Thoracic Cancer. 2023. doi:10.1111/1759-7714.14807

BibTeX
@article{Nishimura2023,
  author = {Nishimura, Tadashi and Fujiwara, Takumi and Fujimoto, Hajime and Tarumi, Hirotoshi and Tsuji, Chikashi and Iwanaka, Soichi and Sakakura, Yasumasa and Naito, Masahiro and Okugawa, Yoshinaga and Yasuma, Taro and Gabazza, Esteban Cesar and Oomoto, Yasuhiro and Kobayashi, Tetsu and Ibata, Hidenori},
  title = {Next‐generation sequencing clarified why first‐line treatment with osimertinib was ineffective in an autopsied case of EGFR ‐mutated lung squamous cell carcinoma},
  journal = {Thoracic Cancer},
  year = {2023},
  doi = {10.1111/1759-7714.14807}
}
Kostenlos starten →